Crispr Therapeutics Ag's Revenue in the fiscal year 2025 $ 3.51 millions
Crispr Therapeutics Ag's Revenue in the fiscal year 2024 $ 37.31 millions
Crispr Therapeutics Ag's Revenue in the fiscal year 2023 $ 371.21 millions
Crispr Therapeutics Ag's Revenue in the fiscal year 2022 $ 1.20 millions
Crispr Therapeutics Ag's Revenue in the fiscal year 2021 $ 914.96 millions
CRSP Revenue second quarter 2026 Y/Y Growth Comment
Crispr Therapeutics Ag reported Revenue surge of 1043.93% year on year in the second quarter 2026, to $ 10.18 millions, this is lower than Crispr Therapeutics Ag's recent average Revenue surge of 9223.92%.
Looking into second quarter 2026 results within Biotechnology & Pharmaceuticals industry 39 other companies have achieved higher Revenue growth. While Crispr Therapeutics Ag' s Revenue doubling of 1043.93% ranks overall at the positon no. 2549 in the second quarter 2026.
CRSP Revenue ( Y/Y Growth %)
2026
2025
2024
2023
4th Quarter
December
-
-97.59 %
-82.26 %
2012000 %
3rd Quarter
September
-
48.33 %
-
-
2nd Quarter
June
1043.93 %
71.15 %
-99.26 %
43650 %
1st Quarter
March
67.82 %
74 %
-99.5 %
10538.3 %
FY
-
-90.59 %
-89.95 %
-
Financial Statements
Crispr Therapeutics Ag's second quarter 2026 Revenue
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Crispr Therapeutics Ag's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
1666566.67 %
46562.67 %
-100 %
(Mar 31 2023)
CRSP's II. Quarter Q/Q Revenue Comment
Crispr Therapeutics Ag achieved in the II. Quarter 2026 below company average Revenue doubling of 597.33% quarter on quarter, to $ 10.18 millions.
II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 2.3% in the II. Quarter a year ago.
Within Biotechnology & Pharmaceuticals industry 3 other companies have achieved higher Revenue quarter on quarter growth. While Crispr Therapeutics Ag's Revenue growth quarter on quarter, overall rank is 42.
Crispr Therapeutics Ag achieved in the II. Quarter 2026 below company average Revenue doubling of 597.33% quarter on quarter, to $ 10.18 millions.
II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 2.3% in the II. Quarter a year ago.
Within Biotechnology & Pharmaceuticals industry 3 other companies have achieved higher Revenue quarter on quarter growth. While Crispr Therapeutics Ag's Revenue growth quarter on quarter, overall rank is 42.
Crispr Therapeutics Ag's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Jun 30 2026)
12 Months Ending (Mar 31 2026)
12 Months Ending (Dec 31 2025)
12 Months Ending (Sep 30 2025)
12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending
$ 13.39
$ 4.10
$ 3.51
$ 38.34
$ 38.05
Y / Y Revenue Growth (TTM)
-64.8 %
-89.11 %
-90.59 %
-81.1 %
-
Year on Year Revenue Growth Overall
Ranking
# 3722
# 3517
# 751
# 1606
# 0
Seqeuential Revenue Change (TTM)
226.4 %
16.89 %
-90.84 %
0.75 %
1 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 2549
# 2167
# 751
# 1607
# 3231
Cumulative Revenue growth Comment
Crispr Therapeutics Ag showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Crispr Therapeutics Ag's annual Revenue improvement would be -64.8% year on year to $13 millions.
In the Healthcare sector 527 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3517 to 3722.
Crispr Therapeutics Ag showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Crispr Therapeutics Ag's annual Revenue drop would be -64.8% year on year to $13 millions.
In the Healthcare sector 527 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3517 to 3722.
About Crispr Therapeutics Ag Revenue Growth Rates (CRSP), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
1,775.43%